Chinese blood products started late and developed rapidly
Blood is the lifeblood of human survival. China's blood products are related to the national health undertaking and bear important social responsibilities.
Liu Wenfang, professor of the Chengdu Institute of Blood Transfusion, Chinese Academy of Medical Sciences, told the 3rd China Economic Outlook Forum “Biopharmaceuticals and National Health Forum†that blood products are a new discipline and industry originating from the development and development of transfusion medicine. The invention of the low-temperature ethanol method to modern blood products has been going on for more than 60 years.
Professor Zhang Jingang, a professor at the 9th Academy of Military Medical Sciences of China, said at the forum that blood products are a product of war demand. Due to the expansion of World War II, the wounded were in urgent need of a large amount of blood for treatment, and the defects and supply of fresh blood caused delays in the wounded. The time of treatment. Entrusted by the United States military, the Cohn Research Group of Harvard University in the United States launched and established a large-scale plasma protein process in 1939. Most of the current processes of blood product manufacturers in the world are the improvement or simplification of the Cohn process. It can be argued that without the need for war, the modern blood products industry will at least postpone its formation. At present, albumin and other drugs are still necessary for the treatment of wounded and surgical operations, and they are also one of the national reserve materials.
Liu Wenfang told reporters that China's large-scale production of blood products started late, and all manufacturers did not really form mass production until the 1990s.
Minister of Health Chen Hao introduced at the forum. At present, China's standardized management of blood products has been continuously strengthened, and a complete quality supervision system for plasma collection stations and a production quality supervision system for blood products have been established. Blood products basically meet the clinical needs.
In 1996, China promulgated and implemented the “Regulations on the Administration of Blood Productsâ€, which laid down a clear requirement for plasma management of raw materials, production, operation and management, supervision and management, and laid a legal foundation for the standardized management of blood products. Since 2005, it has implemented a key regulatory system for blood product manufacturing enterprises; in 2007, it implemented a system for the quarantine of raw materials and a supervisory system for production companies; in 2008, it implemented a batch issue system and the production and distribution of blood products was included in the electronic supervision code management. In 2011, the new version of pharmaceutical GMP was implemented.
The data shows that there were 24 product manufacturing enterprises that had production capacity and were put into production at the end of 2010. At present, there has been an increase in the production of blood products and the amount of apheresis plasma collected in China. In 2009, the blood production enterprises in the country produced a total of 7.7 million bottles of human serum albumin, and the human coagulation factor VIII was 238,000 bottles by 2010. Produced 956.6 million bottles of human serum albumin, and increased the clotting factor of humans to 342,000 bottles. In 2008, 143 apheresis plasma stations throughout the country collected 3,131 tons of apheresis plasma, rose to 156 in 2010, and rose to 4180 in apheresis plasma. Ton.
China will implement a "doubling" plan for blood products
Chen Hao said that blood products are basic and necessary special drugs for the treatment of various diseases in modern medicine, which are scarce and irreplaceable and belong to national strategic resources. Their production and supply are related to national security and social stability, and are related to deepening the medical and health system. Reform the overall situation.
Zhang Jingang said that blood is the lifeblood for human survival. Blood and blood products have the dual characteristics of medical products and drugs. Compared with other drugs, blood and blood products are irreplaceable and irreplaceable, and have a direct bearing on the people’s livelihood. It is even one of the indicators to measure the level of social and economic development of a country. At present, the global strain on medical blood has become a problem faced by medical institutions in various countries. Research on new blood components, plasma protein products and blood substitutes has become an important part of drug development and development.
Currently, hemophilia is a disease with a strong dependence on blood products. Chu Yujia, President of the Chinese Blood Friendship House, said at the sub-forum that there are currently 400,000 people with hemophilia in the world, and that the Chinese population accounts for 21% of the world’s population. The incidence of hemophilia does not differ geographically or ethnically. About 8 million patients (65-13 million), but currently registered 9326 hemophilia patients in China.
Therefore, Liu Wenfang believes that China's blood products bear important social responsibilities. It is necessary to increase scientific research and increase plasma utilization.
At the same time, Liu Wenfang said that in recent years, China's raw material plasma collection volume decline trend is obvious, China's 30 - 40 plasma protein product companies can only reach the plasma production volume of plasma processing - 30 - 50%, but due to insufficient raw material plasma supply There is a serious shortage of plasma protein products.
It is no small matter related to national health. Chen Hao said at the forum that “we proposed to formulate a 'doubling' plan for the implementation of blood products, striving to double the supply of blood products during the 12th Five-Year Plan, and to achieve a goal that is safe to reach. Does not allow a person with hemophilia to die because of a shortage of drugs."
Blood is the lifeblood of human survival. China's blood products are related to the national health undertaking and bear important social responsibilities.
Liu Wenfang, professor of the Chengdu Institute of Blood Transfusion, Chinese Academy of Medical Sciences, told the 3rd China Economic Outlook Forum “Biopharmaceuticals and National Health Forum†that blood products are a new discipline and industry originating from the development and development of transfusion medicine. The invention of the low-temperature ethanol method to modern blood products has been going on for more than 60 years.
Professor Zhang Jingang, a professor at the 9th Academy of Military Medical Sciences of China, said at the forum that blood products are a product of war demand. Due to the expansion of World War II, the wounded were in urgent need of a large amount of blood for treatment, and the defects and supply of fresh blood caused delays in the wounded. The time of treatment. Entrusted by the United States military, the Cohn Research Group of Harvard University in the United States launched and established a large-scale plasma protein process in 1939. Most of the current processes of blood product manufacturers in the world are the improvement or simplification of the Cohn process. It can be argued that without the need for war, the modern blood products industry will at least postpone its formation. At present, albumin and other drugs are still necessary for the treatment of wounded and surgical operations, and they are also one of the national reserve materials.
Liu Wenfang told reporters that China's large-scale production of blood products started late, and all manufacturers did not really form mass production until the 1990s.
Minister of Health Chen Hao introduced at the forum. At present, China's standardized management of blood products has been continuously strengthened, and a complete quality supervision system for plasma collection stations and a production quality supervision system for blood products have been established. Blood products basically meet the clinical needs.
In 1996, China promulgated and implemented the “Regulations on the Administration of Blood Productsâ€, which laid down a clear requirement for plasma management of raw materials, production, operation and management, supervision and management, and laid a legal foundation for the standardized management of blood products. Since 2005, it has implemented a key regulatory system for blood product manufacturing enterprises; in 2007, it implemented a system for the quarantine of raw materials and a supervisory system for production companies; in 2008, it implemented a batch issue system and the production and distribution of blood products was included in the electronic supervision code management. In 2011, the new version of pharmaceutical GMP was implemented.
The data shows that there were 24 product manufacturing enterprises that had production capacity and were put into production at the end of 2010. At present, there has been an increase in the production of blood products and the amount of apheresis plasma collected in China. In 2009, the blood production enterprises in the country produced a total of 7.7 million bottles of human serum albumin, and the human coagulation factor VIII was 238,000 bottles by 2010. Produced 956.6 million bottles of human serum albumin, and increased the clotting factor of humans to 342,000 bottles. In 2008, 143 apheresis plasma stations throughout the country collected 3,131 tons of apheresis plasma, rose to 156 in 2010, and rose to 4180 in apheresis plasma. Ton.
China will implement a "doubling" plan for blood products
Chen Hao said that blood products are basic and necessary special drugs for the treatment of various diseases in modern medicine, which are scarce and irreplaceable and belong to national strategic resources. Their production and supply are related to national security and social stability, and are related to deepening the medical and health system. Reform the overall situation.
Zhang Jingang said that blood is the lifeblood for human survival. Blood and blood products have the dual characteristics of medical products and drugs. Compared with other drugs, blood and blood products are irreplaceable and irreplaceable, and have a direct bearing on the people’s livelihood. It is even one of the indicators to measure the level of social and economic development of a country. At present, the global strain on medical blood has become a problem faced by medical institutions in various countries. Research on new blood components, plasma protein products and blood substitutes has become an important part of drug development and development.
Currently, hemophilia is a disease with a strong dependence on blood products. Chu Yujia, President of the Chinese Blood Friendship House, said at the sub-forum that there are currently 400,000 people with hemophilia in the world, and that the Chinese population accounts for 21% of the world’s population. The incidence of hemophilia does not differ geographically or ethnically. About 8 million patients (65-13 million), but currently registered 9326 hemophilia patients in China.
Therefore, Liu Wenfang believes that China's blood products bear important social responsibilities. It is necessary to increase scientific research and increase plasma utilization.
At the same time, Liu Wenfang said that in recent years, China's raw material plasma collection volume decline trend is obvious, China's 30 - 40 plasma protein product companies can only reach the plasma production volume of plasma processing - 30 - 50%, but due to insufficient raw material plasma supply There is a serious shortage of plasma protein products.
It is no small matter related to national health. Chen Hao said at the forum that “we proposed to formulate a 'doubling' plan for the implementation of blood products, striving to double the supply of blood products during the 12th Five-Year Plan, and to achieve a goal that is safe to reach. Does not allow a person with hemophilia to die because of a shortage of drugs."
Surgical Gowns,Disposible Surgical Gowns,Anti-Virus Surgical Gowns,Medical Isolation Surgical Gowns
Zhende Medical Co.,Ltd , https://www.zdmedicalproduct.com